Stomach Virus Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • Biopharmaceutical company Immuron has provided results on its research and development to Travelan (travellers diarrhea).
  • The research conducted treated 12 monkeys in two groups – placebo cohort of four and Travelan treatment cohort of eight.

Every year, there are an estimated 1.5 billion episodes of this disease worldwide. These episodes result in the deaths of approximately 2.2 million people, mostly children in developing countries. Walter Reed Army Institute of Research has been developing vaccines against Shigella for over 10 years.

Travelan is an orally administered immunotherapy which reduces the likeliness of travellers contracting diarrhoea. Travelan is a listed medicine on the Australian Register for Therapeutic Goods and is indicated to reduce the risk of Travellers’ Diarrhoea and reduces the risk of other gastro-intestinal disorders.

The Shigella challenge model was used to assess the therapeutic potential of Travelan as a prevention treatment for shigellosis or dysentry. The study is placebo-controlled and was carried out in 12 rhesus monkeys segregated into two groups: a Travelan treatment cohort of eight and a placebo cohort of four.

Placebo-treated animals displayed severe clinical signs of dysentry within 24-36 hours and inflammation in the gastro-intestinal tract. Only two of the eight Travelan-treated group displayed any signs of dysentry, while the remaining six remained healthy.

“The study results clearly demonstrated that animals with severe inflammation in the gastrointestinal tract and high inflammatory cytokines in fecal samples were associated with severe dysentery and that prophylactic administration of Travelan significantly reduced the inflammatory response,” Dr Robert Kaminski, Walter Reed Army Institute of Research said.

The study findings will be presented at the 10th International conference on Vaccines for Enteric Diseases which will be held in Switzerland in October, 2019.

Immuron CEO, Dr Gary Jacob said: “The work completed by our research collaborators at the WRAIR has clearly demonstrated the effectiveness of TravelanĀ® and the Immuron technology platform in neutralizing pathogenic gastrointestinal bacterial infections.”

He continued to state Travelan could be a significantly beneficial preventative treatment for US military personnel and civilians when travelling.

IMC by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.